Therapeutics: c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene); epidermal growth factor receptor (EGFR); EGFR1 (HER1; ErbB1)


INDICATION: Non-small cell lung cancer (NSCLC)

Cell culture and mouse studies suggest combined inhibition of c-MET and EGFR could help treat NSCLC. In co-cultures of

Read the full 246 word article

How to gain access

Continue reading with a
two-week free trial.